Tryptophan hydroxylase gene and major psychoses.
Disturbances of the serotoninergic neurotransmitter system have been implicated in the pathogenesis of mood disorders. The tryptophan hydroxylase (TPH) gene, which codes for the rate-limiting enzyme of serotonin biosynthesis, has been recently reported to be associated with bipolar disorder. In this study, we investigated TPH A218C gene variants in a sample of subjects affected by major psychoses. One thousand four hundred and twenty-four inpatients affected by bipolar (n=627), major depressive (n=511), schizophrenic (n=210), delusional (n=48) disorder and psychotic disorder not otherwise specified (n=27) (DSM-IV) were included; all patients and 380 controls were typed for the TPH variants using PCR techniques. A sub-sample of 963 patients was assessed using the Operational Criteria for Psychotic Illness (OPCRIT). TPH variants were not associated with major psychoses, but a trend was observed toward an excess of TPH*A/A in bipolar disorder. The analysis of symptomatology factors did not show any significant difference either; however, a trend was observed for males with the TPH*A genotype to have lower depressive symptoms compared with TPH*C subjects. Possible stratification factors such as current age and age of onset did not affect the observed results. TPH A218C variants are not, therefore, a major liability factor for the symptoms of major psychoses to have in the present sample. TPH*A containing variants may be a protective factor for depressive symptoms among male subjects with mood disorders or for a subtype of mood disorders characterized by a mainly manic form of symptomatology.
Serretti
A
A
Department of Psychiatry, Vita-Salute University, San Raffaele Institute, Milan, Italy. serreti.alessandro@hsr.it
Lilli
R
R
Lorenzi
C
C
Lattuada
E
E
Cusin
C
C
Smeraldi
E
E
D000328:Adult; D001714:Bipolar Disorder / Q000201:enzymology / Q000235:genetics; D004252:DNA Mutational Analysis; D017931:DNA Primers / Q000235:genetics; D005260:Female; D015870:Gene Expression / Q000235:genetics*; D005787:Gene Frequency; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000494:pharmacology; D017354:Point Mutation / Q000235:genetics; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic / Q000235:genetics; D011618:Psychotic Disorders / Q000201:enzymology* / Q000235:genetics*; D011985:Receptors, Serotonin / Q000187:drug effects / Q000378:metabolism*; D012563:Schizophrenia, Paranoid / Q000201:enzymology / Q000235:genetics; D012701:Serotonin / Q000096:biosynthesis; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D014365:Tryptophan Hydroxylase / Q000235:genetics* / Q000378:metabolism*
D017931:DNA Primers; D010879:Piperazines; D011985:Receptors, Serotonin; D017366:Serotonin Receptor Agonists; D012701:Serotonin; D014365:Tryptophan Hydroxylase; C015068:1-(3-chlorophenyl)piperazine